AMGEN Inc (AMGN) Dividends

Amgen's dividend offers an attractive 2.69% yield, which is above the sector average for large-cap pharmaceuticals, providing immediate income appeal. The company has demonstrated a commitment to growing its dividend over time, which is a positive signal for income investors. However, a deeper analysis using the GoodMoat framework reveals critical sustainability risks. The primary concern is the balance sheet, where a Debt/Equity ratio of 6.3 far exceeds the framework's favourable threshold of low/zero debt (Debt/EBITDA < 1.0x). This high leverage indicates the dividend is being paid from a position of financial strain rather than strength. On the cash flow side, the picture is mixed. A Free Cash Flow Yield of 4.3% suggests the current dividend is covered by cash generation, but the margin for error is thin given the massive debt load. The payout ratio, while not explicitly provided, can be inferred to be manageable given the 21% profit margin, but the company's capital allocation is heavily skewed towards servicing its debt rather than organically reinforcing its business moat. For a value investor focused on durable income, the combination of a strong yield and growth history is favourable, but the extreme leverage is a severe red flag that places the long-term sustainability of the payout under a cloud of caution. Analysis based on data as of 2024-05-15.